Harmony Biosciences
HRMY · Nasdaq · United States
Share price · HRMY
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when HRMY's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 4 Nov 2026-7.0%
- 22 Oct 2026-6.0%
Nothing announced by HRMY that day or the session before.
- 4 Aug 2026+8.9%
- 21 Jul 2026+10.0%
- 10 Jun 2026+4.0%
Nothing announced by HRMY that day or the session before.
- 21 Apr 2026+8.8%
Nothing announced by HRMY that day or the session before.
- 23 Feb 2026-7.9%
Nothing announced by HRMY that day or the session before.
- 20 Feb 2026-15.2%
Nothing announced by HRMY that day or the session before.
- 18 Feb 2026-4.4%
Nothing announced by HRMY that day or the session before.
- 13 Jan 2026-6.6%
Share of unusual movement by asset
For each asset, the share of HRMY's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(3 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | Histamine H3 receptor (antagonist / inverse agonist)Small molecule | Myotonic Dystrophy Type 1NarcolepsyIdiopathic HypersomniaPrader-Willi Syndrome | |
| Phase 3 | Histamine H1 receptor · Serotonin receptors (5-HT)Small molecule | EpilepsyDravet SyndromeLennox-Gastaut Syndrome | |
| Preclinical / Unstaged | Histamine H3 receptor (antagonist / inverse agonist)Small molecule | Narcolepsy |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(3)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $269M | $72M | $647M+ $124M short-term inv. | —$77M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $261M | $47M | $550M+ $118M short-term inv. | —$92M operating cash flow | report ↗ |
| 2026-Q1 | $215M | $69M | $590M+ $52M short-term inv. | —$28M operating cash flow | report ↗ |
| 2025-Q3 | $239M | $55M | $647M+ $26M short-term inv. | —$109M operating cash flow | report ↗ |
| 2025-Q2 | $200M | $50M | $546M+ $19M short-term inv. | —$79M operating cash flow | report ↗ |
| 2025-Q1 | $185M | $35M | $489M+ $18M short-term inv. | —$34M operating cash flow | report ↗ |
| 2024-Q3 | $186M | $25M | $388M+ $23M short-term inv. | —$71M operating cash flow | report ↗ |
| 2024-Q2 | $173M | $64M | $318M+ $30M short-term inv. | —$43M operating cash flow | report ↗ |
| 2024-Q1 | $155M | $22M | $333M+ $39M short-term inv. | —$31M operating cash flow | report ↗ |
| 2023-Q3 | $160M | $18M | $325M+ $46M short-term inv. | —$63M operating cash flow | report ↗ |
| 2023-Q2 | $134M | $15M | $318M+ $54M short-term inv. | —$37M operating cash flow | report ↗ |
| 2023-Q1 | $119M | $13M | $289M+ $56M short-term inv. | —$43M operating cash flow | report ↗ |
| 2022-Q3 | $117M | $41M | $262M+ $46M short-term inv. | —$55M operating cash flow | report ↗ |
| 2022-Q2 | $107M | $13M | $237M+ $18M short-term inv. | —$34M operating cash flow | report ↗ |
| 2022-Q1 | $85M | $7.6M | $225M | —$29M operating cash flow | report ↗ |
| 2021-Q3 | $81M | $12M | $190M | $9.6M$30M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $868M | $190M | $753M+ $23M short-term inv. | —$348M operating cash flow | report ↗ |
Harmony Biosciences reported full-year 2025 revenue of $868.45M, up 21.5% YoY, with R&D spend of $189.59M, up 30.0% YoY. The company ended the period with cash and equivalents of $752.77M and reported net income of $158.69M.
The company reiterated 2026 WAKIX net revenue guidance of $1.0–$1.04 billion. It completed settlements with three additional generic filers, bringing total settled ANDA filers to six of seven, and received FDA approval for the pediatric cataplexy indication in February. Pitolisant GR NDA submission remains on track for Q2 2026, Phase 3 topline data for pitolisant in Prader-Willi syndrome is expected in 2H 2026, the orexin-2 agonist (BP1.15205) Phase 1 trial is ongoing with data expected in mid-2026, and EPX-100 Phase 3 trials in Dravet syndrome and Lennox-Gastaut syndrome have topline data anticipated in 1H 2027.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $715M | $146M | $453M+ $14M short-term inv. | —$220M operating cash flow | report ↗ |
| 2023-FY | $582M | $76M | $312M+ $42M short-term inv. | —$219M operating cash flow | report ↗ |
| 2022-FY | $438M | $71M | $245M+ $79M short-term inv. | —$144M operating cash flow | report ↗ |
| 2021-FY | $305M | $30M | $235M | —$99M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 13 sales ($6.0M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-09-18 | Budur Kumar · CHIEF MEDICAL OFFICER | Option exercise | 10,406 | $30.69 | $319K | Form 4 |
| 2026-09-18 | Budur Kumar · CHIEF MEDICAL OFFICER | Option exercise | 25,446 | $30.27 | $770K | Form 4 |
| 2026-09-18 | Budur Kumar · CHIEF MEDICAL OFFICER | Open-market sale | 35,852 | $43.05 | $1.5M | Form 4 |
| 2026-09-18 | Budur Kumar · CHIEF MEDICAL OFFICER | Option exercise (derivative) | 10,406 | — | — | Form 4 |
| 2026-09-18 | Budur Kumar · CHIEF MEDICAL OFFICER | Option exercise (derivative) | 25,446 | — | — | Form 4 |
| 2026-09-17 | Budur Kumar · CHIEF MEDICAL OFFICER | Option exercise | 400 | $30.69 | $12K | Form 4 |
| 2026-09-17 | Budur Kumar · CHIEF MEDICAL OFFICER | Option exercise | 400 | $30.27 | $12K | Form 4 |
| 2026-09-17 | Budur Kumar · CHIEF MEDICAL OFFICER | Open-market sale | 800 | $43.00 | $34K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 308 reporting institutions held 55.6M shares ($1.4B, 94.6% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BlackRock, Inc. | 7,070,035 | $198.0M |
| 2 | FMR LLC | 3,157,639 | $88.4M |
| 3 | VANGUARD PORTFOLIO MANAGEMENT LLC | 2,714,353 | $76.0M |
| 4 | AMERICAN CENTURY COMPANIES INC | 2,105,179 | $59.0M |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 2,102,315 | $58.9M |
| 6 | DIMENSIONAL FUND ADVISORS LP | 2,076,510 | $58.2M |
| 7 | STATE STREET CORP | 1,784,362 | $50.0M |
| 8 | ARMISTICE CAPITAL, LLC | 1,624,000 | $45.5M |
| 9 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 1,382,113 | $38.7M |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 1,322,720 | $37.1M |
| 11 | GOLDMAN SACHS GROUP INC | 1,239,207 | $34.7M |
| 12 | RENAISSANCE TECHNOLOGIES LLC | 1,077,371 | $30.2M |
| 13 | MORGAN STANLEY | 1,031,018 | $28.9M |
| 14 | MILLENNIUM MANAGEMENT LLC | 954,359 | $26.7M |
| 15 | JPMORGAN CHASE & CO | 823,513 | $22.2M |